1 in 4 Patients With NSCLC Respond Poorly to COVID-19 Vaccine
About 1 in 4 patients with non–small cell lung cancer have an unsatisfactory antibody response to the Omicron variant following COVID-19 vaccination, reports a new study.
MDedge News
source https://www.medscape.com/viewarticle/978694?src=rss
MDedge News
source https://www.medscape.com/viewarticle/978694?src=rss
Comments
Post a Comment